Trial NCT00912444

View at ClinicalTrials.gov 
Org. Study IDs: NATT

Last trial update was posted on 2016-11-22

MeSH Interventions

Cyclophosphamide Docetaxel Doxorubicin Epirubicin

MeSH Conditions

Breast Neoplasms

Other Conditions

Breast Cancer

Stopping Reasons

TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID